Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H19N3O5 |
Molecular Weight | 333.3392 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O
InChI
InChIKey=LLEUXCDZPQOJMY-AAEUAGOBSA-N
InChI=1S/C16H19N3O5/c17-11(5-6-14(20)21)15(22)19-13(16(23)24)7-9-8-18-12-4-2-1-3-10(9)12/h1-4,8,11,13,18H,5-7,17H2,(H,19,22)(H,20,21)(H,23,24)/t11-,13-/m0/s1
Oglufanide, an angiogenesis inhibitor, an immunomodulator, that originally was developed and registered in Russia under the brand name timogen. Oglufanide inhibits vascular endothelial growth factor (VEGF), which may inhibit angiogenesis. This agent has also been reported to stimulate the immune response to hepatitis C virus and intracellular bacterial infections. Oglufanide was studied in the USA for the treatment of cancer, and in September 2001, it was granted Orphan Drug designation for the treatment of ovarian cancer. In addition, in Australia this drug was involved in phase II clinical trial for the treatment of hepatitis C. Oglufanide is also participated in phase III trials for patients with Kaposi's sarcoma, however, this study was discontinued.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Effects of structural and "mixed" isomers of Glu-Trp dipeptide on normal hemopoietic stem cells. | 2006 Feb |
|
The effects of the EW dipeptide optical and chemical isomers on the CFU-S population in intact and irradiated mice. | 2007 Mar |
|
Oral absorption enhancement of dipeptide L-Glu-L-Trp-OH by lipid and glycosyl conjugation. | 2008 |
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1742
Created by
admin on Sat Dec 16 17:09:55 GMT 2023 , Edited by admin on Sat Dec 16 17:09:55 GMT 2023
|
||
|
NCI_THESAURUS |
C308
Created by
admin on Sat Dec 16 17:09:55 GMT 2023 , Edited by admin on Sat Dec 16 17:09:55 GMT 2023
|
||
|
FDA ORPHAN DRUG |
126799
Created by
admin on Sat Dec 16 17:09:55 GMT 2023 , Edited by admin on Sat Dec 16 17:09:55 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C76274
Created by
admin on Sat Dec 16 17:09:55 GMT 2023 , Edited by admin on Sat Dec 16 17:09:55 GMT 2023
|
PRIMARY | |||
|
38101-59-6
Created by
admin on Sat Dec 16 17:09:55 GMT 2023 , Edited by admin on Sat Dec 16 17:09:55 GMT 2023
|
PRIMARY | |||
|
CHEMBL2111029
Created by
admin on Sat Dec 16 17:09:55 GMT 2023 , Edited by admin on Sat Dec 16 17:09:55 GMT 2023
|
PRIMARY | |||
|
DB05779
Created by
admin on Sat Dec 16 17:09:55 GMT 2023 , Edited by admin on Sat Dec 16 17:09:55 GMT 2023
|
PRIMARY | |||
|
334073
Created by
admin on Sat Dec 16 17:09:55 GMT 2023 , Edited by admin on Sat Dec 16 17:09:55 GMT 2023
|
PRIMARY | |||
|
4RHY598T5U
Created by
admin on Sat Dec 16 17:09:55 GMT 2023 , Edited by admin on Sat Dec 16 17:09:55 GMT 2023
|
PRIMARY | |||
|
300000001583
Created by
admin on Sat Dec 16 17:09:55 GMT 2023 , Edited by admin on Sat Dec 16 17:09:55 GMT 2023
|
PRIMARY | |||
|
100094
Created by
admin on Sat Dec 16 17:09:55 GMT 2023 , Edited by admin on Sat Dec 16 17:09:55 GMT 2023
|
PRIMARY | |||
|
8146
Created by
admin on Sat Dec 16 17:09:55 GMT 2023 , Edited by admin on Sat Dec 16 17:09:55 GMT 2023
|
PRIMARY | |||
|
73512
Created by
admin on Sat Dec 16 17:09:55 GMT 2023 , Edited by admin on Sat Dec 16 17:09:55 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)